Best of Obesity Forum: Personalizing Management and Case Challenges
This activity is supported by educational grants from Lilly and Novo Nordisk, Inc.
Click Here to Manage Email Alerts
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by educational grants from Lilly and Novo Nordisk, Inc.
Activity Description
Obesity continues to be a significant health concern worldwide. According to the World Health Organization (WHO), obesity rates have tripled since 1975, and in 2016, more than 1.9 billion adults were overweight, with 650 million of them classified as obese. The prevalence of obesity varies by region, with the highest rates observed in North America, Europe, and the Middle East. In the United States, the obesity rate is particularly high, with more than one-third of adults classified as obese. Obesity is associated with numerous health complications, including an increased risk of cardiovascular disease, stroke, type 2 diabetes mellitus, sleep apnea, gallbladder disease, osteoarthritis, and certain types of cancer. It also contributes to a lower quality of life and increased healthcare costs. Among the groups at risk for obesity are youths aged 2 to 19 years, of whom 19.3% are estimated to have obesity. Efforts to combat obesity include lifestyle interventions such as diet and exercise, anti-obesity medications, and surgery. However, the ongoing rise in obesity rates suggests that more work is needed to address this global health challenge. This session, Personalizing Management and Case Challenges, will incorporate didactic presentations covering the patient experience; pharmacological management of obesity including addressing negative perceptions and rationale for its use; obesity in children and adolescents; and interactive, case-based discussions.
Target Audience
The intended audience for this activity is endocrinologists, family medicine physicians, internists, pharmacists, dietitians, nurse practitioners, physician associates, and other healthcare professionals involved in the management of patients with overweight and obesity.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Select patients with overweight and obesity who may be at high risk of complications and may benefit from timely interventions for weight management.
- Incorporate interprofessional coordination of care, patient preferences/perspectives, and shared decision-making regarding evidence-based obesity treatments.
- Discuss the negative perceptions associated with early-generation anti-obesity medications (AOMs), improvements in the safety and efficacy profiles of current AOMs, and rationale for their early use in clinical practice.
- Implement the most recent clinical data for medication management of overweight and obesity in children and adolescents.
- Apply the pharmacological management of overweight and obesity based on evidence-based interventions, patient needs, and recent and long-term clinical data including evidence regarding weight regain after cessation of medication.
Activity Chair
Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL
Faculty
Holly Herrington, MS, RD, LDN, CDCES
Advanced Clinical Dietitian
Center for Lifestyle Medicine and Bariatric Surgery
Northwestern Memorial Hospital
Chicago, IL
Scott Kahan, MD, MPH, FTOS, DABOM
Director, National Center for Weight and Wellness
Johns Hopkins Bloomberg School of Public Health
Washington, DC
Elizabeth Paul, MA
PATIENT ADVOCATE
Board Member, Obesity Action Coalition
Director of Development, Connections Ministry
Mankato, MN
Donna H. Ryan, MD, FACP, FTOS
Professor Emerita
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, LA
Edmond P. Wickham III, MD, MPH, DABOM, FAAP
Associate Professor of Internal Medicine and Pediatrics
Division of Endocrinology, Diabetes and Metabolism
Co-Director, Healthy Lifestyles Center
Children’s Hospital of Richmond
Virginia Commonwealth University
Richmond, VA
Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participants who opt in by providing their ABIM ID and DOB (MM/DD) will earn MOC points equivalent to the amount of CME credits claimed for the activity.
This program is acceptable for 2.25 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number is JA0006104-0000-23-029-H01-P, effective 10/31/2023. This is a knowledge-based activity, and there is no fee to attend.
Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.
This activity is approved for 2.25 contact hour(s) of continuing education (which includes 1.5 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 23106404. This activity was planned in accordance with AANP Accreditation Standards and Policies.
American Academy of Physician Associates (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME. PAs may receive a maximum of 2.25 credit hours for completing this program.
This enduring material is approved for 1 year from the date of original release, October 31, 2023, to October 30, 2024.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 6 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AANP Contact Hour Certificate, or Statement of Continuing Pharmacy Education Credit.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Holly Herrington, MS, RD, LDN, CDCES
No relevant financial relationships to disclose.
Scott Kahan, MD, MPH, FTOS, DABOM
Consultant: Gelesis, Lilly, Novo Nordisk, Pfizer, Vivus
Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Consultant: Altimmune, Boehringer Ingelheim, Lilly, Novo Nordisk, Pfizer, WeightWatchers
Elizabeth Paul, MA
Advisor: Boehringer Ingelheim, Pfizer
Speaker Contracted by Ineligible Company: Boehringer Ingelheim, Lilly
Donna H. Ryan, MD, FACP, FTOS
Advisor: Altimmune, Calibrate, Gila Therapeutics, Lilly, Novo Nordisk, Real Appeal,
Wondr Health, Xeno, YSOPIA, Zealand
Consultant: Amgen, IFA Celtic, Scientific Intake, Wondr Health
Speaker Contracted by Ineligible Company: IFA Celtic, Novo Nordisk
Independent Research Contractor: Lilly, Rhythm
Data Safety Monitoring Board: IQVIA
SELECT Steering Committee: Novo Nordisk
Edmond P. Wickham III, MD, MPH, DABOM, FAAP
No relevant financial relationships to disclose.
Planners/Reviewers report the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at cme@vindicoCME.com